Trevena (TRVN) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
TRVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Trevena, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.012 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.001 |
| Beta | 0.60 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.29% |
| 3 Year Change | -99.97% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Trevena Q2 2022 Earnings Preview
Aug 10Trevena slides on $2M preferred stock offering
Jul 29Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely
Jul 08
Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?
Mar 19Trevena Offers An Enticing Risk-Reward At These Prices
Dec 14Trevena: Remaining Patient After A Disappointing Q2 Earnings
Aug 17Shareholder Returns
| TRVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.3% |
| 1Y | -99.3% | 27.1% | 15.8% |
Return vs Industry: TRVN underperformed the US Biotechs industry which returned 26.7% over the past year.
Return vs Market: TRVN underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| TRVN volatility | |
|---|---|
| TRVN Average Weekly Movement | 30.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRVN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TRVN's weekly volatility has decreased from 3567% to 31% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Carrie Bourdow | www.trevena.com |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc. Fundamentals Summary
| TRVN fundamental statistics | |
|---|---|
| Market cap | US$11.51k |
| Earnings (TTM) | -US$34.04m |
| Revenue (TTM) | US$546.00k |
Is TRVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRVN income statement (TTM) | |
|---|---|
| Revenue | US$546.00k |
| Cost of Revenue | US$1.59m |
| Gross Profit | -US$1.04m |
| Other Expenses | US$33.00m |
| Earnings | -US$34.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -35.50 |
| Gross Margin | -190.48% |
| Net Profit Margin | -6,233.70% |
| Debt/Equity Ratio | -141.0% |
How did TRVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 21:59 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trevena, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| Ritu Baral | Canaccord Genuity |
| Brandon Folkes | Cantor Fitzgerald & Co. |